OncLive TV

Mark Leick, MD, discusses the challenges and limitations associated with the use of CAR T-cell therapy across hematologic malignancies, highlighting how ongoing research may potentially ameliorate present unmet needs.

Miguel Villalona-Calero, MD, discusses interim data from a phase 1/2 investigation of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma and highlights the ongoing evaluation of the agent’s safety.

John Lindsay Marshall, MD, discusses the significance of the FDA approval of fruquintinib (Fruzaqla) in patients with metastatic colorectal cancer.

Marina Baretti, MD, discusses innate and acquired mechanisms of resistance in patients with unresectable, advanced, or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements.

Paul D. Nathan, MBBS, PhD, FRCP, discusses the 3-year survival data from the phase 3 IMCgp100-202 trial of tebentafusp-tebn in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma.

Jesus Berdeja, MD, discusses the current role of BCMA-targeted therapies in multiple myeloma, and imparts advice to colleagues regarding the sequencing of bispecific antibodies and CAR T-cell therapies.

Arlene O. Siefker-Radtke, MD, discusses the efficacy of erdafitinib in patients with metastatic urothelial cancer with select FGFR alterations in the phase 3 THOR study.

Cathy Eng, MD, FACP, FASCO, discusses the ongoing investigation of fruquintinib in patients with relapsed/refractory metastatic colorectal cancer.

Maria Pia Morelli, MD, PhD, discusses the ongoing investigation of A2B530, a Tmod™ CAR T-cell therapy, in advanced or metastatic solid tumors and highlights forward-facing research with the agent.

Arnold Etame, MD, PhD, discusses the effects of a patient’s socioeconomic status on the cancer treatment options they receive.

Mark Leick, MD, discusses the varying role of CAR T-cell therapy across various hematologic malignancies, elaborating on the cause of its effectiveness in these disease spaces.

Ze'ev Ronai, PhD, discusses key advancements in the treatment of patients with melanoma, including the discovery of NRAS and BRAF mutations, as well as the development of immunotherapy approaches.

Allison A. DiPasquale, MD, discusses the continued evaluation of Cerianna positron emission tomography scans in patients with breast cancer and highlights the need for a multidisciplinary approach when treating patients in this population.

Pasi A. Jänne, MD, PhD, discusses the mechanism of action of the novel KRAS G12C RAS(ON) inhibitor RMC-6291, which is being evaluating for the treatment of patients with KRAS-mutated solid tumors.

John Shen, MD, discusses unique features associated with the use of the prostate-specific membrane antigen–directed antibody-drug conjugate ARX517 in patients with metastatic castration-resistant prostate cancer and highlights early efficacy and safety findings with this agent.

Neeta Somaiah, MD, discusses enrollment criteria for the phase 3 Peak trial in patients with gastrointestinal stromal tumor and the advantages of this trial’s design.

Moshe Kelsen, MBA, discusses ongoing initiatives that aim to improve diversity, equity, and inclusion for patients with cancer receiving treatment at Columbia University.

R. Jonathan Henderson, MD, discusses incorporating immunotherapy agents into practice in patients with bladder cancer.

Benjamin H. Lowentritt, MD, FACS, discusses the exploration of active surveillance in patients with prostate cancer.

David Morris, MD, FACS, discusses the best practices for active surveillance in low- and intermediate-risk patients with prostate cancer, highlighting factors to look for in patients undergoing active surveillance that may point to the need for further treatment.

E. David Crawford, MD, discusses the evolving role of active surveillance in patients with prostate cancer.

Rami Komrokji, MD, discusses the benefit of agents such as luspatercept-aamt in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with erythropoiesis-stimulating agents.

Marina Baretti, MD, discusses the evolving utility of FGFR inhibitors in the treatment of patients with unresectable, advanced, or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

Gautam Jayram, MD, discusses the current indications for immunotherapy agents in the bladder cancer treatment paradigm, as well as immune-related adverse effects to be aware of when treating patients who are receiving these therapies.

Daniel Spratt, MD, discusses research findings that have delineated the optimal sequencing of radiation therapy and hormone therapy for patients with prostate cancer.

Jorge Nieva, MD, discusses the rationale and design of an ongoing phase 2 trial investigating a telemedicine approach to delivering subcutaneous atezolizumab for patients with non–small cell lung cancer.

Misty D. Shields, MD, PhD, discusses systemic therapy updates for patients with extensive-stage small cell lung cancer.

Benjamin Creelan, MD, discusses the investigation of A2B530 in patients with advanced or metastatic non–small cell lung cancer.

John Michael Kaczmar, MD, discusses future implications for the use of fianlimab in combination with cemiplimab for the treatment of patients with advanced melanoma.

Funda Meric-Bernstam, MD, discusses results from the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki in HER2-expressing solid tumors.